In patients whose aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher than 40 IU/L at treatment initiation, the median AST and ALT levels were significantly higher in the no-HCC group (Ps < 0.05). This evidence concerns the gene GPT and hepatocellular carcinoma.